Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Deferred Revenue: 2015-2024

Historic Current Deferred Revenue for Cartesian Therapeutics (RNAC) over the last 8 years, with Mar 2024 value amounting to $412,000.

  • Cartesian Therapeutics' Current Deferred Revenue fell 95.77% to $412,000 in Q1 2024 from the same period last year, while for Mar 2024 it was $412,000, marking a year-over-year decrease of 95.77%. This contributed to the annual value of $5.8 million for FY2023, which is 886.34% up from last year.
  • As of Q1 2024, Cartesian Therapeutics' Current Deferred Revenue stood at $412,000, which was down 92.96% from $5.8 million recorded in Q4 2023.
  • In the past 5 years, Cartesian Therapeutics' Current Deferred Revenue registered a high of $115.8 million during Q3 2020, and its lowest value of $412,000 during Q1 2024.
  • For the 3-year period, Cartesian Therapeutics' Current Deferred Revenue averaged around $11.6 million, with its median value being $9.1 million (2023).
  • Per our database at Business Quant, Cartesian Therapeutics' Current Deferred Revenue crashed by 99.09% in 2022 and then spiked by 886.34% in 2023.
  • Quarterly analysis of 5 years shows Cartesian Therapeutics' Current Deferred Revenue stood at $110.8 million in 2020, then crashed by 41.06% to $65.3 million in 2021, then plummeted by 99.09% to $593,000 in 2022, then spiked by 886.34% to $5.8 million in 2023, then crashed by 95.77% to $412,000 in 2024.
  • Its Current Deferred Revenue was $412,000 in Q1 2024, compared to $5.8 million in Q4 2023 and $8.1 million in Q3 2023.